Safety and Tolerability Study of Voreloxin and Cytarabine Combination in Acute Myeloid Leukemia in Humans
Completed · Phase 1/Phase 2
Conditions studied: Acute Myeloid Leukemia
In brief
This study will evaluate the safety and tolerability of voreloxin (vosaroxin) injection in combination with cytarabine in patients with relapsed or refractory acute myeloid leukemia.
Key facts
- Study ID
- NCT00541866
- Run by
- Sunesis Pharmaceuticals
- People needed
- 110
- Starts
- 2007-10-06
- Expected to finish
- 2012-02-15
- Last updated by the study team
- 2018-01-09
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- HealthOne Presbyterian/St. Luke's Medical Center — Denver, Colorado, United States
- Rocky Mountain Cancer Centers — Denver, Colorado, United States
- H. Lee Moffitt Cancer Center — Tampa, Florida, United States
- Northwestern Medical Faculty Foundation — Chicago, Illinois, United States
- Northwestern Memorial Hospital — Chicago, Illinois, United States
- Indiana University Cancer Center — Indianapolis, Indiana, United States
- Johns Hopkins University - Sidney Kimmel Cancer Center — Baltimore, Maryland, United States
- New York Presbyterian Hospital-Weill Cornell Medical College — New York, New York, United States
- MD Anderson Cancer Center — Houston, Texas, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.